Aurinia Pharmaceuticals Inc. (AUPH) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Aurinia Pharmaceuticals’s revenue went from $173000 in fiscal 2016 to $283M in fiscal 2025, growth of about 127.6% a year.
Net income in fiscal 2025 was $287M, a net margin of 101.5%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $322M and net income $314M.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $322M | $283M | $235M | $176M | $134M | $46M | $50M | $318000 | $463000 | $418000 | $173000 |
| Gross profit | $292M | $250M | $207M | $161M | $128M | $45M | $50M | $318000 | — | — | — |
| Operating income | $156M | $105M | -$5M | -$92M | -$111M | -$181M | -$104M | -$91M | -$55M | -$47M | -$25M |
| Net income | $314M | $287M | $6M | -$78M | -$108M | -$181M | -$103M | -$88M | -$53M | -$71M | -$23M |
| EPS (diluted) | $2.29 | $2.14 | $0.04 | $-0.58 | $-0.81 | $-1.35 | $-0.77 | $-0.66 | $-0.40 | $-0.53 | $-0.17 |
| R&D | $48M | $33M | $21M | $50M | $45M | $51M | $50M | $53M | $41M | — | — |
| Revenue growth | — | +20.4% | +34.0% | +30.9% | +193.9% | −9.0% | +15660.4% | −31.3% | +10.8% | +141.6% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $177M | $136M | $44M | -$33M | -$80M | -$158M | -$70M | -$64M | -$52M | -$41M | -$19M |
| Capital spending | -$135000 | — | — | $0 | $0 | -$1M | -$2M | $0 | $0 | -$25000 | -$15000 |
| Free cash flow | $177M | — | — | -$33M | -$80M | -$159M | -$72M | -$64M | -$52M | -$41M | -$19M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $75M | $98M | $40M | $0 | $0 | — | — | — | — | — | — |
| Stock-based pay | $15M | $15M | $32M | $45M | $32M | $31M | $17M | $7M | $7M | $4M | $1M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $398M | $358M | $350M | $389M | $466M | $398M | $306M | $126M | $173M | $40M |
| Debt | — | $6M | $7M | $8M | $8M | $9M | $8M | — | $0 | $0 | $0 |
| Equity | — | $581M | $377M | $378M | $405M | $479M | $408M | $299M | $136M | $178M | $36M |
| Total assets | — | $752M | $551M | $548M | $471M | $543M | $464M | $324M | $146M | $190M | $57M |
| Shares (diluted) | 135M | 134M | 134M | 134M | 134M | 134M | 134M | 134M | 134M | 134M | 134M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 90.6% | 88.5% | 88.0% | 91.9% | 95.8% | 97.6% | 100.0% | 100.0% | — | — | — |
| Operating margin | 48.6% | 37.1% | -2.0% | -52.2% | -83.2% | -396.3% | -208.1% | -28598.4% | -11930.9% | -11212.4% | -14466.5% |
| Net margin | 97.7% | 101.5% | 2.5% | -44.5% | -80.7% | -396.8% | -204.9% | -27794.0% | -11464.1% | -16935.9% | -13465.3% |
| FCF margin | 55.0% | — | — | -19.1% | -59.3% | -348.4% | -142.7% | -19995.3% | -11147.1% | -9855.0% | -10825.4% |
| ROIC | — | 14.1% | -0.9% | -18.8% | -21.3% | -29.3% | -25.0% | -24.1% | -32.1% | -26.3% | -55.0% |
| ROE | — | 49.4% | 1.5% | -20.6% | -26.7% | -37.8% | -25.2% | -29.6% | -39.1% | -39.8% | -64.8% |
Frequently asked questions
What is Aurinia Pharmaceuticals’s annual revenue?
$283M in fiscal 2025 and $322M over the twelve months to September 30, 2026.
How much profit does Aurinia Pharmaceuticals make?
Net income was $287M in fiscal 2025 (net margin 101.5%).
Is Aurinia Pharmaceuticals’s revenue growing?
Yes: revenue rose 20.4% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.